Expertise in
25
conditions

Dr. Alexander D. Colevas

Oncology
Tanya W Spirtos MD Wommens Cancer
900 Blake Wilbur Dr, 
Palo Alto, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
25
conditions
Tanya W Spirtos MD Wommens Cancer
900 Blake Wilbur Dr, 
Palo Alto, CA 

Overview

Alexander Colevas is an Oncologist practicing medicine in Palo Alto, California.

Dr. Colevas is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Oral Squamous Cell Carcinoma, and Thyroid Cancer.

He is actively involved in clinical research, co-authoring 146 peer reviewed articles and participating in 12 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MD

Hospital Affiliations

Stanford Health Care Tri-Valley
Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Tanya W Spirtos MD Wommens Cancer
900 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Enrollment Status: Recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 1
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drug: VK-2019
Study Phase: Phase 2
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: CUE-101, Pembrolizumab
Study Phase: Phase 1
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer
Enrollment Status: Completed
Publish Date: March 27, 2025
Intervention Type: Drug, Biological
Study Drugs: Gedeptin, Fludarabine
Study Phase: Phase 1/Phase 2
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer
A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Enrollment Status: Terminated
Publish Date: August 15, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3
View 9 Less Clinical Trials

146 Total Publications

Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 27, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (0.1 miles away)
650-498-6000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (1.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristen Ganjoo is an Oncologist practicing medicine in Palo Alto, California. Dr. Ganjoo is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (1.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joel Neal is an Oncologist practicing medicine in Palo Alto, California. Dr. Neal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Thymic Epithelial Tumor, and Tissue Biopsy.

Frequently Asked Questions about Dr. Alexander D. Colevas

How do I make an appointment with Dr. Alexander D. Colevas?

You can book an appointment with Dr. Alexander D. Colevas by calling their office at 650-498-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alexander D. Colevas a top-rated expert for Nasopharyngeal Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alexander D. Colevas is classified as an Elite expert for Nasopharyngeal Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alexander D. Colevas specialize in?

While Dr. Alexander D. Colevas is a Oncology, they have specific expertise in Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Oral Squamous Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Alexander D. Colevas participate in research or clinical trials?

Yes. Dr. Alexander D. Colevas has published 146 articles and abstracts on conditions like Nasopharyngeal Carcinoma. You can view a list of Dr. Alexander D. Colevas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alexander D. Colevas accept my insurance?

Dr. Alexander D. Colevas accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 650-498-6000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Colevas's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 16 Advanced Conditions
View All 50 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile